Your Daily Pharma Scoop: TGTX Positive Data In MS, Iovance Trial Delay [Seeking Alpha]
IMMUNE DESIGN CORP COMMON STOCK (IMDZ)
Last immune design corp common stock earnings: 11/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.immunedesign.com/investor-relations
Company Research
Source: Seeking Alpha
Summary TGTX showed positive phase 2 data in relapsing MS. After its initial hiccup earlier with its CLL drug, this news should bolster the stock a little. Iovance has been asked by the FDA to add another fresh cohort of patients, delaying the trial to H2 2020. TG Therapeutics' ublituximab showed treatment benefit in mid-stage MS study Nanocap TG Therapeutics ( TGTX ) announced positive results from a phase 2 study of its lead candidate ublituximab (TG-1101) in patients with relapsing multiple sclerosis. Patients saw only annualized relapse rate of 0.07, and at week 48, 93% of patients were relapse free. For a less than half a billion dollar company trading near its 52-week lows, with $136mn in cash and almost $100mn in annualized cash burn, this is good news indeed, and makes for an interesting investing opportunity. TG-1101 is a next generation anti CD20 antibody that has shown treatment benefit in rituxan refractory patients, a class of MS patients with poo
Show less
Read more
Impact Snapshot
Event Time:
IMDZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMDZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMDZ alerts
High impacting IMMUNE DESIGN CORP COMMON STOCK news events
Weekly update
A roundup of the hottest topics